Sino Biopharmaceutical Limited (SBP Group) submitted its Monthly Return for Equity Issuer for the period ended 31 August 2026, confirming a stable capital structure during the month.

As at 31 August 2026, authorised share capital remained unchanged at 30.00 billion ordinary shares with a par value of HKD 0.025 each, equivalent to HKD 750.00 million. Issued share capital also stayed flat at 18.68 billion ordinary shares, and the company held no treasury shares. No new shares were issued, no shares were repurchased or cancelled, and no share options were exercised, resulting in zero funds raised from option exercises.

The company affirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 25 %, maintaining sufficient free-float liquidity.

No activity occurred under the 15 June 2023 share-option scheme, with zero options outstanding or newly granted. Warrants and convertible securities remain non-applicable.

SBP Group reiterated its obligation to issue 14.60 million ordinary shares to Dracoo Investment Limited as partial consideration for the RMB 1.20 billion acquisition of Hangzhou Hygieia Biomedical Co., Ltd., completed on 30 March 2026. The shares are scheduled for allotment in two tranches: 5.84 million shares by 29 April 2028 and 8.76 million shares by 29 April 2029.

Overall, the August return underscores capital stability, with no dilution or buybacks and clear disclosure of future share issuances linked to prior M&A commitments.